BidaskClub Downgrades Dynavax Technologies (DVAX) to Hold

BidaskClub cut shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a report published on Wednesday.

DVAX has been the topic of a number of other reports. Cowen reissued an outperform rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Thursday, August 10th. Cantor Fitzgerald began coverage on shares of Dynavax Technologies in a report on Friday, September 15th. They set an overweight rating and a $24.00 target price on the stock. ValuEngine raised shares of Dynavax Technologies from a sell rating to a hold rating in a report on Thursday, September 7th. Royal Bank Of Canada reissued a buy rating and set a $26.00 target price on shares of Dynavax Technologies in a report on Friday, September 1st. Finally, William Blair reissued an outperform rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Dynavax Technologies presently has an average rating of Buy and an average target price of $25.17.

Shares of Dynavax Technologies (NASDAQ:DVAX) opened at $18.30 on Wednesday. Dynavax Technologies has a twelve month low of $3.70 and a twelve month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm’s revenue was down 68.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.90) earnings per share. equities analysts expect that Dynavax Technologies will post -1.72 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of DVAX. GMT Capital Corp increased its holdings in shares of Dynavax Technologies by 1.7% in the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock worth $65,735,000 after acquiring an additional 52,300 shares during the period. Vanguard Group Inc. increased its holdings in shares of Dynavax Technologies by 10.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock worth $19,538,000 after acquiring an additional 199,004 shares during the period. PointState Capital LP acquired a new stake in shares of Dynavax Technologies in the 2nd quarter worth about $13,510,000. State Street Corp increased its holdings in shares of Dynavax Technologies by 19.7% in the 2nd quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock worth $8,099,000 after acquiring an additional 138,112 shares during the period. Finally, C WorldWide Group Holding A S increased its holdings in shares of Dynavax Technologies by 23.3% in the 3rd quarter. C WorldWide Group Holding A S now owns 823,825 shares of the biopharmaceutical company’s stock worth $17,712,000 after acquiring an additional 155,610 shares during the period. 70.61% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Dynavax Technologies (DVAX) to Hold” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/12/10/bidaskclub-downgrades-dynavax-technologies-dvax-to-hold.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit